Sun Pharma Advanced Research slashes jobs in major shake-up

Business Jan 08, 2026

Sun Pharma Advanced Research Company (SPARC) is making big changes—cutting 40% of its staff and letting go of over 80% of its US team as it looks to optimize cost and boost growth.

Streamlining labs, but costs may rise

SPARC has trimmed its labs from four to two and transitioned from a fully captive model to a hybrid model, saving $10 million a year.
Still, relying more on outside clinical trials could push some expenses back up.

Looking ahead: funding plans & a legal win

The company's planning for future funding with extra support from promoters and internal cash.
On the bright side, SPARC just scored a legal victory in the US tied to its epilepsy drug Sezaby—a reminder that their research pipeline still has promise.